PCSK9: Patients with high Lipoprotein (a) could benefit more

被引：0
|
作者：
Franke, Katharina
机构：
来源：
AKTUELLE KARDIOLOGIE | 2019年 / 8卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
    Schwartz, Gregory G.
    Szarek, Michael
    Bittner, Vera A.
    Diaz, Rafael
    Goodman, Shaun G.
    Jukema, J. Wouter
    Landmesser, Ulf
    Lopez-Jaramillo, Patricio
    Manvelian, Garen
    Pordy, Robert
    Scemama, Michel
    Sinnaeve, Peter R.
    White, Harvey D.
    Steg, Ph Gabriel
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 78 (05) : 421 - 433
  • [2] PCSK9 Association With Lipoprotein(a)
    Tavori, Hagai
    Christian, Devon
    Minnier, Jessica
    Plubell, Deanna
    Shapiro, Michael D.
    Yeang, Calvin
    Giunzioni, Ilaria
    Croyal, Mikael
    Duell, P. Barton
    Lambert, Gilles
    Tsimikas, Sotirios
    Fazio, Sergio
    CIRCULATION RESEARCH, 2016, 119 (01) : 29 - +
  • [3] Lipoprotein(a) and Benefit of PCSK9 Inhibition in Emergency Complex Higher-risk and Indicated Patients
    Jin, Zhi-li
    He, Tao
    Peng, Li
    Wu, Xiao-yan
    Fan, Di
    Chen, Ming
    Fan, Yong-zhen
    Guo, Yuan-lin
    Lu, Zhi-bing
    Wang, Hai-rong
    CURRENT MEDICAL SCIENCE, 2023, 43 (06) : 1206 - 1212
  • [4] Lipoprotein(a) and Benefit of PCSK9 Inhibition in Emergency Complex Higher-risk and Indicated Patients
    Zhi-li Jin
    Tao He
    Li Peng
    Xiao-yan Wu
    Di Fan
    Ming Chen
    Yong-zhen Fan
    Yuan-lin Guo
    Zhi-bing Lu
    Hai-rong Wang
    Current Medical Science, 2023, 43 : 1206 - 1212
  • [5] Lipoprotein(a) in the advent of a PCSK9 world
    Kotani, Kazuhiko
    ANNALS OF CLINICAL BIOCHEMISTRY, 2020, 57 (01) : 102 - 102
  • [6] PCSK9 and Lipoprotein(a) The Plot Thickens
    Toth, Peter P.
    CIRCULATION RESEARCH, 2016, 119 (01) : 3 - 6
  • [7] Effect of PCSK9 inhibition with alirocumab on lipoprotein(a) in patients with high risk of cardiovascular disease
    Safdar, S.
    Cramb, R.
    Dawson, C.
    ATHEROSCLEROSIS SUPPLEMENTS, 2017, 28 : E12 - E12
  • [8] Effects of lipoprotein apheresis on PCSK9 levels
    Julius, U.
    Milton, M.
    Stoellner, D.
    Rader, D.
    Gordon, B.
    Polk, D.
    Waldmann, E.
    Parhofer, K. G.
    Moriarty, P. M.
    ATHEROSCLEROSIS SUPPLEMENTS, 2015, 18 : 180 - 186
  • [9] Lipoprotein(a) and PCSK9 inhibition: clinical evidence
    Ruscica, Massimiliano
    Greco, Maria Francesca
    Ferri, Nicola
    Corsini, Alberto
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0L) : L53 - L56
  • [10] Lipoprotein (a), arterial inflammation, and PCSK9 inhibition
    Tardif, Jean-Claude
    Rheaume, Eric
    Rhainds, David
    Dube, Marie-Pierre
    EUROPEAN HEART JOURNAL, 2019, 40 (33) : 2782 - 2784
12345